The toxicity profile of TAS-102. Practical considerations about neutropenia.
TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. Albeit generally well tolerated, clinically relevant neutropenia may interfere with the regular delivery of full-dose cycles with a possible detrimental effect on the dose-intensity. Judicious and personalized use of colony-stimulating growth factors as well as alterative schedules of drug delivery could mitigate neutropenia, so contributing to an even better therapeutic index of the drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 110(2019), 7 vom: 05. Juli, Seite 325-329 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Il profilo di tossicità del TAS-102. Considerazioni pratiche in tema di neutropenia |
|---|
| Beteiligte Personen: |
Zaniboni, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
56HH86ZVCT |
|---|
| Anmerkungen: |
Date Completed 28.01.2020 Date Revised 09.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3197.31743 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299906396 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299906396 | ||
| 003 | DE-627 | ||
| 005 | 20231225101349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3197.31743 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM299906396 | ||
| 035 | |a (NLM)31379366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Zaniboni, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The toxicity profile of TAS-102. Practical considerations about neutropenia. |
| 246 | 3 | 3 | |a Il profilo di tossicità del TAS-102. Considerazioni pratiche in tema di neutropenia |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2020 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. Albeit generally well tolerated, clinically relevant neutropenia may interfere with the regular delivery of full-dose cycles with a possible detrimental effect on the dose-intensity. Judicious and personalized use of colony-stimulating growth factors as well as alterative schedules of drug delivery could mitigate neutropenia, so contributing to an even better therapeutic index of the drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Pyrrolidines |2 NLM | |
| 650 | 7 | |a trifluridine tipiracil drug combination |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Thymine |2 NLM | |
| 650 | 7 | |a QR26YLT7LT |2 NLM | |
| 650 | 7 | |a Trifluridine |2 NLM | |
| 650 | 7 | |a RMW9V5RW38 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 110(2019), 7 vom: 05. Juli, Seite 325-329 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2019 |g number:7 |g day:05 |g month:07 |g pages:325-329 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3197.31743 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2019 |e 7 |b 05 |c 07 |h 325-329 | ||